{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:04:14Z","timestamp":1790345054137,"version":"4.1.0"},"reference-count":35,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"DOI":"10.1080\/14737167.2026.2737568","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:55:56Z","timestamp":1790009756000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness and value implications of veligrotug versus teprotumumab for moderate-to-severe thyroid eye disease in the United States"],"prefix":"10.1080","author":[{"given":"Zhengxuan","family":"Li","sequence":"first","affiliation":[{"name":"University of Houston","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Weng","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Houston","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moosa","family":"Tatar","sequence":"additional","affiliation":[{"name":"University of Houston","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/105072502761016476"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1420591"},{"issue":"1","key":"e_1_3_7_5_1","first-page":"1","article-title":"Progressive exophthalmos","volume":"15","author":"Naffziger HC","year":"1954","unstructured":"Naffziger HC. Progressive exophthalmos. Ann R Coll Surg Engl. 1954;15(1):1\u201324.","journal-title":"Ann R Coll Surg Engl"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000894"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000529"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S193018"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2025.1565762"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.04.013"},{"key":"e_1_3_7_11_1","volume-title":"Thyroid eye disease","author":"Shah SS","year":"2026","unstructured":"Shah SS, Stokkermans TJ, Patel BC. Thyroid eye disease. Treasure Island (FL): StatPearls. StatPearls Publishing Copyright \u00a9 2026, StatPearls Publishing LLC.; 2026."},{"issue":"1","key":"e_1_3_7_12_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40123-020-00318-x","article-title":"Physician-perceived impact of thyroid eye disease on patient quality of life in the United States","volume":"10","author":"Wang Y","year":"2021","unstructured":"Wang Y, Sharma A, Padnick-Silver L, et al. Physician-perceived impact of thyroid eye disease on patient quality of life in the United States. Ophthalmol Ther. 2021;10(1):75\u201387.","journal-title":"Ophthalmol Ther"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa140"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.14740\/jem997"},{"key":"e_1_3_7_15_1","doi-asserted-by":"crossref","unstructured":"Ugradar S Shi L Wang Y et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye (Lond). 2021;35(9):2607\u20132612.","DOI":"10.1038\/s41433-020-01297-w"},{"issue":"17","key":"e_1_3_7_16_1","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","article-title":"Teprotumumab: a review in thyroid eye disease","volume":"82","author":"Nie T","year":"2022","unstructured":"Nie T, Lamb YN. Teprotumumab: a review in thyroid eye disease. Drugs. 2022;82(17):1663\u20131670.","journal-title":"Drugs"},{"issue":"4","key":"e_1_3_7_17_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas RS","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u2013352.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_7_18_1","first-page":"36","article-title":"Teprotumumab (tepezza) for thyroid eye disease","volume":"119","author":"Couch SM","year":"2022","unstructured":"Couch SM. Teprotumumab (tepezza) for thyroid eye disease. Mo Med. 2022;119(1):36\u201341.","journal-title":"Mo Med"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0043"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14101027"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad637"},{"key":"e_1_3_7_22_1","unstructured":"Viridian Therapeutics Inc. Viridian Therapeutics announces U.S. FDA approval and launch of Lumvoa\u2122 (veligrotug-vvze) for the treatment of thyroid eye disease. 2026. Jun 26. Available from: https:\/\/investors.viridiantherapeutics.com\/news\/news-details\/2026\/Viridian-Therapeutics-Announces-U-S--FDA-Approval-and-Launch-of-Lumvoa-veligrotug-vvze-for-the-Treatment-of-Thyroid-Eye-Disease\/default.aspx"},{"key":"e_1_3_7_23_1","unstructured":"Viridian Therapeutics I. Lumvoa (veligrotug-vvze) full prescribing information. Viridian Therapeutics Inc.; 2026."},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.2240"},{"issue":"8","key":"e_1_3_7_25_1","first-page":"4302","article-title":"Veligrotug (VRDN-001), a full antagonist monoclonal antibody to IGF-1 receptor, in active Thyroid Eye Disease (TED): thrive phase 3 efficacy and safety topline results","volume":"66","author":"Turbin R","year":"2025","unstructured":"Turbin R, Leibowitz S, Yen MT, et al. Veligrotug (VRDN-001), a full antagonist monoclonal antibody to IGF-1 receptor, in active Thyroid Eye Disease (TED): thrive phase 3 efficacy and safety topline results. Invest Ophthalmol Visual Sci. 2025;66(8):4302.","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"1","key":"e_1_3_7_26_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices\u2013modeling studies","volume":"6","author":"Weinstein MC","year":"2003","unstructured":"Weinstein MC, O\u2019Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices\u2013modeling studies. Value Health. 2003;6(1):9\u201317.","journal-title":"Value Health"},{"key":"e_1_3_7_27_1","unstructured":"Amgen Inc. TEPEZZA\u00ae (teprotumumab-trbw) list price\/wholesale acquisition cost. WAC USD 18 721.69 per 500-mg vial accurate as of March 25. 2025. Available from: Amgen product list-pricing disclosure."},{"key":"e_1_3_7_28_1","unstructured":"Dunleavy K. Look out Amgen. Here comes Viridian with FDA nod for TED med Lumvoa. Fierce Pharma; 2026. Jun 29. Available from: https:\/\/www.fiercepharma.com\/pharma\/look-out-amgen-here-comes-viridian-fda-nod-ted-med-lumvoa"},{"key":"e_1_3_7_29_1","volume-title":"Medicare Physician Fee Schedule, calendar year 2026 (drug administration, CPT 96365\/96366)","author":"Centers for Medicare & Medicaid Services","year":"2026","unstructured":"Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule, calendar year 2026 (drug administration, CPT 96365\/96366). Baltimore (MD): CMS; 2026."},{"issue":"7","key":"e_1_3_7_30_1","first-page":"4002","article-title":"Comparison of treatment cost and quality-of-life impact of thyroid eye disease therapies","volume":"63","author":"Shah SA","year":"2022","unstructured":"Shah SA, Lu T, Yu M, et al. Comparison of treatment cost and quality-of-life impact of thyroid eye disease therapies. Invest Ophthalmol Vis Sci. 2022;63(7):4002\u2013A0344.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0083"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189"},{"key":"e_1_3_7_33_1","volume-title":"Presented at: American Academy of Ophthalmology Annual Meeting","author":"Douglas RS","year":"2021","unstructured":"Douglas RS, Francis-Sedlak M, Holt RJ, et al. Real-world adherence with teprotumumab in ted [poster]. Presented at: American Academy of Ophthalmology Annual Meeting; New Orleans, LA; 2021 Nov 12\u201315. Poster PO026."},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000002280"},{"issue":"1","key":"e_1_3_7_35_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ophtha.2024.07.018","article-title":"The rate of Retreatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow-up","volume":"132","author":"Ugradar S","year":"2025","unstructured":"Ugradar S, Parunakian E, Malkhasyan E, et al. The rate of Retreatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow-up. Ophthalmology. 2025;132(1):92\u201397.","journal-title":"Ophthalmology"},{"issue":"11","key":"e_1_3_7_36_1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn BJ","year":"2021","unstructured":"Winn BJ, Kersten RC. Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies. Ophthalmology. 2021;128(11):1627\u20131651.","journal-title":"Ophthalmology"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae560"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2737568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737167.2026.2737568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2737568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:31:47Z","timestamp":1790343107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2737568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":35,"alternative-id":["10.1080\/14737167.2026.2737568"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2737568","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}